Have a feature idea you'd love to see implemented?
Let us know!
CKPT Checkpoint Therapeutics Inc
Price (delayed)
$3.47
Market cap
$169.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.84
Enterprise value
$164.75M
Checkpoint Therapeutics, Inc. ('Checkpoint') is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is
Highlights
CKPT's EPS has surged by 59% year-on-year and by 3.2% since the previous quarter
The equity has grown by 34% YoY and by 20% from the previous quarter
CKPT's net income is up by 14% YoY but it is down by 9% QoQ
CKPT's gross profit has plunged by 73% YoY and by 40% from the previous quarter
Checkpoint Therapeutics's revenue has shrunk by 73% YoY and by 40% QoQ
Key stats
What are the main financial stats of CKPT
Market
Valuations
Earnings
Shares outstanding
48.83M
Market cap
$169.45M
Enterprise value
$164.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3,185.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,505.23
Revenue
$47,000
EBIT
-$46.47M
EBITDA
-$46.47M
Free cash flow
-$30.76M
Per share
Balance sheet
Liquidity
EPS
-$1.84
Free cash flow per share
-$0.71
Book value per share
-$0.28
Revenue per share
$0
TBVPS
$0.12
Total assets
$5.18M
Total liabilities
$17.77M
Debt
$0
Equity
-$12.59M
Working capital
-$12.59M
Debt to equity
0
Current ratio
0.29
Quick ratio
0.26
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
-98,868.1%
Gross margin
100%
Net margin
-98,868.1%
Operating margin
-79,817%
Return on assets
-659.1%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-98,868.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CKPT stock price
How has the Checkpoint Therapeutics stock price performed over time
Intraday
2.66%
1 week
-8.2%
1 month
9.12%
1 year
61.4%
YTD
51.53%
QTD
54.91%
Financial performance
How have Checkpoint Therapeutics's revenue and profit performed over time
Revenue
$47,000
Gross profit
$47,000
Operating income
-$37.51M
Net income
-$46.47M
Gross margin
100%
Net margin
-98,868.1%
The company's operating margin has shrunk by 133% YoY and by 75% QoQ
CKPT's net margin has dropped by 82% since the previous quarter
CKPT's gross profit has plunged by 73% YoY and by 40% from the previous quarter
Checkpoint Therapeutics's revenue has shrunk by 73% YoY and by 40% QoQ
Growth
What is Checkpoint Therapeutics's growth rate over time
Valuation
What is Checkpoint Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
3,185.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,505.23
CKPT's EPS has surged by 59% year-on-year and by 3.2% since the previous quarter
The equity has grown by 34% YoY and by 20% from the previous quarter
CKPT's price to sales (P/S) is 185% higher than its last 4 quarters average of 1118.2
Checkpoint Therapeutics's revenue has shrunk by 73% YoY and by 40% QoQ
Efficiency
How efficient is Checkpoint Therapeutics business performance
CKPT's return on sales has dropped by 82% since the previous quarter
The return on assets is up by 9% year-on-year and by 2.1% since the previous quarter
Dividends
What is CKPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CKPT.
Financial health
How did Checkpoint Therapeutics financials performed over time
The total assets is 71% less than the total liabilities
The company's current ratio has surged by 190% YoY and by 12% QoQ
The total assets has soared by 133% YoY but it has contracted by 9% from the previous quarter
CKPT's debt is 100% greater than its equity
The equity has grown by 34% YoY and by 20% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.